|By PR Newswire||
|February 17, 2014 08:32 AM EST||
NEW YORK, Feb. 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the UK's pharmaceutical industry in recent years. According to RNCOS' research report, "UK Injectables Market Outlook to 2017", the market is anticipated to grow at a CAGR of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving this market.
The said report is a study of the UK injectable market in terms of major therapeutic areas. It covers the historical sales trend of injectables for categories such as Diabetes, Vaccines, Sex Hormones & Antagonist in Malign Disease, Anticoagulants & Protamine, Hypothalamic & Pituitary Hormones, Rheumatic Diseases & Gout, etc. Not only this, the report also provides the sales trend of the top 10 injectable drugs in the UK market along with a rational analysis.
Certain pharmaceutical firms in UK's injectable market have established their foothold given the diverse and innovative product offerings. Several small pharma majors too have been aggressively competing with big pharmaceutical players in order to establish themselves in the market. The report highlights a detailed comparison of the market shares of different players in the injectables market.
The study provides an insight about the competitive landscape, which includes business profiling and a strength-weakness analysis of top pharmaceutical players in the UK injectable business. There's also a coverage of the detailed analysis of their top injectable drugs in terms of revenue.
A lot of investment is being done in research and development of injectables in order to improve their medical outcomes. Here it is worth mentioning that even the country's government has significantly contributed towards the development of innovative medicines.
Moreover, the Government has shifted its focus towards cost effective drug treatments by fixing up the drug prices as per their clinical value. In addition, there are a set of regulations that support the injectable drug business in the country. In this context, various regulatory processes such as drug licensing, marketing/ promotion, pricing etc. have been comprehensively covered in the report. In a nutshell, the report covers every aspect of UK injectables which will help the industry players to take strategic decisions.
1. Analyst View
2. Research Methodology
3. UK Injectables Market Outlook to 2017
3.1 Current and Future Market Analysis
3.1.1 By Top 10 Injectables
3.1.2 By Top 10 Therapeutics
3.1.3 By Major Players
4. Drivers and Challenges
5. Regulatory Environment
6. Competitive Landscape
6.1 Novo Nordisk
6.1.1 Business Overview
6.1.2 Key Injectable Sales
6.1.3 Strengths and Weaknesses
6.1.4 Recent Developments
6.2.1 Business Overview
6.2.2 Key Injectable Sales
6.2.3 Strengths and Weaknesses
6.2.4 Recent Developments
6.3 Eli Lily & Co.
6.3.1 Business Overview
6.3.2 Key Injectable Sales
6.3.3 Strengths and Weaknesses
6.4.1 Business Overview
6.4.2 Key Injectable Sales
6.4.3 Strengths and Weaknesses
6.4.4 Recent Developments
6.5 Abbott Laboratories
6.5.1 Business Overview
6.5.2 Key Injectable Sales
6.5.3 Strengths and Weaknesses
6.5.4 Recent Developments
6.6 Takeda Pharmaceutical Company Ltd
6.6.1 Business Overview
6.6.2 Key Injectable Sales
6.6.3 Strengths and Weaknesses
6.6.4 Recent Developments
List of Figures:
Figure 3-1: Injectables Market (Million £), 2012-2017
Figure 3-2: Injectables Market by Player (%), 2010
Figure 3-3: Injectables Market by Player (%), 2012
Figure 6-1: Novo Nordisk - Break up of Revenue by Business Segment (%), 2012
Figure 6-2: Novo Nordisk - Diabetes Care Revenue by Segment (%), 2012
Figure 6-3: Novo Nordisk UK - Break up of Revenue by Segment (%), 2012
Figure 6-4: Sanofi - Break up of Revenue by Business Segment (%), 2012
Figure 6-5: Eli Lily & Co. - Break up of Revenue by Business Segment (%), 2012
Figure 6-6: Eli Lily & Co. - Human Pharmaceutical Division Revenue by Segment (%), 2012
Figure 6-7: Pfizer - Break up of Revenue by Business Segment (%), 2012
List of Tables:
Table 3-1: Top 10 Injectable Sales (Million £), 2010-2012
Table 3-2: Injectable Sales by Top 10 Therapeutics (Million £), 2010-2012
Table 6-1: Novo Nordisk UK - Key Injectable Sales (Million £), 2010-2012
Table 6-2: Novo Nordisk UK - Strengths and Weaknesses
Table 6-3: Sanofi UK - Key Injectable Sales (Million £), 2010-2012
Table 6-4: Sanofi UK - Strengths and Weaknesses
Table 6-5: Eli Lily & Co. UK - Key Injectable Sales (Million £), 2010-2012
Table 6-6: Eli Lily & Co. UK - Strengths and Weaknesses
Table 6-7: Pfizer UK - Key Injectable Sales (Million £), 2010-2012
Table 6-8: Pfizer UK - Strengths and Weaknesses
Table 6-9: Abbott Laboratories UK - Key Injectable Sales (Million £), 2010-2012
Table 6-10: Abbott Laboratories UK - Strengths and Weaknesses
Table 6-11: Takeda Pharmaceuticals UK - Key Injectable Sales (Million £), 2010-2012
Table 6-12: Takeda Pharmaceuticals UK - Strengths and Weaknesses
To order this report: UK Injectables Market Outlook to 2017
Contact Clare: [email protected]
Intl: +1 339-368-6001
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Mar. 30, 2017 08:00 AM EDT Reads: 4,578
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Mar. 30, 2017 07:15 AM EDT Reads: 463
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Mar. 30, 2017 06:00 AM EDT Reads: 3,149
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
Mar. 30, 2017 05:00 AM EDT Reads: 10,105
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Mar. 30, 2017 04:45 AM EDT Reads: 3,372
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Mar. 30, 2017 04:45 AM EDT Reads: 3,345
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...
Mar. 30, 2017 04:15 AM EDT Reads: 1,009
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Mar. 30, 2017 04:15 AM EDT Reads: 2,279
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Mar. 30, 2017 04:00 AM EDT Reads: 3,320
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Mar. 30, 2017 03:45 AM EDT Reads: 3,495
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
Mar. 30, 2017 02:15 AM EDT Reads: 4,164
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Mar. 30, 2017 01:30 AM EDT Reads: 2,666
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Mar. 30, 2017 01:15 AM EDT Reads: 1,272
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
Mar. 30, 2017 01:00 AM EDT Reads: 8,369
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to max...
Mar. 30, 2017 12:45 AM EDT Reads: 772